Created the first SEA genomic data digitization collaboration to improve access to cancer clinical trials

SINGAPORE, November 3, 2022 /PRNewswire/ — Oncoshot has just announced one of its biggest collaborations to date with the Icon Cancer Center in Singapore, alongside Roche. Together, the partners plan to facilitate more comprehensive genomic profiling data to increase access to more trial options for cancer patients. This first-ever collaboration within SEA will help advance the biopharmaceutical research and development ecosystem for healthcare professionals, institutions and patients by taking a more personalized approach to care and providing people with cancer with more treatment options.

From left to right: Ying Ying Yeoh, Managing Director of Roche Singapore; Serena Wee, CEO of Icon ASEAN and Hong Kong; Dr. Huren Sivaraj, CEO and co-founder of Oncoshot. (Photography by Azfian Bin Anuar; editing by Mel Marc Cornelio)

Currently, the cancer genomic testing process involves taking a biological sample from a patient, after which the test results are returned to the requesting physician. Unless a doctor is aware of an ongoing clinical trial, they are likely to prescribe their patient standard treatment at this point. Through this collaboration, Oncoshot, Icon and Roche will be able to easily identify cancer patients who match existing clinical trials underway within their networks. In addition, real-time population matching will also allow companies and clinical research organizations (CROs) on the Oncoshot clinical trial platform to engage Icon as a preferred clinical trial center, increasing the patient access to clinical trial options for their cancer.

“This collaboration marks our commitment to advancing cancer care and increasing access to the latest cancer clinical trials. By digitizing a patient’s genomic profile, we are able to speed up the process of matching patients to the most appropriate clinical trials,” said Serena peeCEO of Icon ASEAN and hong kong. “By investing in this partnership, our patients can gain faster access to new and emerging advances in cancer treatment, giving them and their families new hope and opportunities.”

“With comprehensive genomic profiling (CGP) data, healthcare professionals can make more informed decisions for their patients about potential treatment options, which should include access to clinical trials of investigational new drugs,” said Ying Ying Yeoh, CEO of Roche Singapore. “We are proud to partner with Oncoshot and Icon to help more patients in our collective fight against cancer and to advance clinical cancer research in Asia Pacific to bring more medicines to patients sooner.

As part of this collaboration, Roche will provide CGP data from assays that analyze more than 300 genes known to promote cancer growth.

About Oncoshot

Oncoshot was founded in 2018 by medical oncologist Dr. Huren Sivaraj and data science engineer Ruslan Enikeev. As a health information exchange platform, Oncoshot leverages its proprietary artificial intelligence clinical trial matching technology to address inefficiencies in cancer clinical trials. The platform serves as a bridge between leading regional healthcare institutions and CROs and global biotech and pharmaceutical companies to facilitate data-driven cancer clinical trials while accelerating enrollment for those actively recruiting.

For more information, visit

About Icon Cancer Center

Icon Cancer Center is a leading private cancer care provider that offers a holistic approach to cancer care. Icon Cancer Center is part of Icon Group, a global provider of cancer care with over 50 centers worldwide. Icon Cancer Center has seven clinics specializing in Singapore and a dedicated medical screening clinic. With an eminent and experienced team of visiting medical oncologists, radiation oncologists, haematologists, pediatric haematologist-oncologists, palliative care specialists, general practitioners and surgical oncologists, Icon provides end-to-end care. bout against cancer, from screening and diagnosis to treatment and beyond.

For more information, visit




Elna M. Lemons